administration, especially in the form of tablets, dragees, capsules, solutions, liquids, gels, plaster, creams, ointments, syrup, slurries, suspensions, spray, nebulizer or suppositories.

13. A compound of formula (I) according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, for use as a medicament.

14. The use of a compound according to any one of claims 1 to 10 for the manufacture of a medicament with ~~as~~ a pharmaceutically active substance having antagonistic activity against the FPR1 receptor.

15. A process for the preparation of a compound according to any one of claims 1 to 10 which comprises

(a) coupling an appropriately functionalized solid support with an appropriately N-protected derivative of that amino acid which in the desired end-product is in position T^1 or T^2 or P^1 to P^{14} as defined above; any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

(b) removing the N-protecting group from the product obtained in step (a);

(c) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is in the position of the next element (T or P), following counterclockwise or clockwise the sequence according to general formula (I) in -COOH to $-NH_2$ orientation; any